The disclosure of cash and cash equivalents is a critical piece of financial information that investors use to assess a company's liquidity and short-term viability. For a biotech company like Oncternal Therapeutics, having a substantial cash reserve is essential for funding ongoing research and operations. This information is likely to be viewed positively by investors, as it suggests that the company has a buffer to sustain its activities, which could lead to a short-term positive impact on the stock price.